Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Global Blood Therapeutics (GBT) plans to submit a marketing authorization application to the European Medicines Agency (EMA) asking that Oxbryta (voxelotor) be approved for treating hemolytic anemia in people ... Read more
Global Blood Therapeutics (GBT) will ask the U.S. Food and Drug Administration (FDA) to allow children with sickle cell disease (SCD), ages 4 to 11, to also be treated with Oxbryta (voxelotor). The company ... Read more
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Forma Therapeutics‘ FT-4202 for the treatment of sickle cell disease (SCD) This designation is given to investigational therapies intended ... Read more
The American Society of Hematology released new clinical guidelines on the use of blood transfusions in people with sickle cell disease (SCD). The transfusion guidelines are the second in ... Read more
Children with sickle cell disease (SCD) who arrive at an emergency department with vaso-occlusive episodes (VOEs) are more likely to have a longer delay before treatment, receive less narcotics ... Read more
Global Blood Therapeutics (GBT) announced the five organizations that will receive more than $200,000 worth of grants through its new Access to Excellent Care for Sickle Cell Patients Pilot ... Read more